Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $154.08

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has been given a consensus recommendation of “Moderate Buy” by the twenty-three research firms that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $154.08.

Several equities research analysts recently weighed in on the company. HC Wainwright boosted their target price on Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. UBS Group upped their price objective on shares of Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Oppenheimer raised their price target on Neurocrine Biosciences from $200.00 to $216.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Finally, Guggenheim boosted their price objective on Neurocrine Biosciences from $164.00 to $170.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 273 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $140.55, for a total value of $38,370.15. Following the sale, the insider now owns 7,507 shares in the company, valued at approximately $1,055,108.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $140.55, for a total value of $38,370.15. Following the completion of the transaction, the insider now owns 7,507 shares in the company, valued at $1,055,108.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gary A. Lyons sold 12,500 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $135.63, for a total value of $1,695,375.00. Following the sale, the director now owns 116,947 shares in the company, valued at approximately $15,861,521.61. The disclosure for this sale can be found here. Insiders sold 80,709 shares of company stock worth $11,009,150 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of large investors have recently modified their holdings of NBIX. RFP Financial Group LLC lifted its holdings in Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after buying an additional 149 shares in the last quarter. Mather Group LLC. acquired a new position in shares of Neurocrine Biosciences during the first quarter valued at $26,000. Lindbrook Capital LLC lifted its stake in shares of Neurocrine Biosciences by 85.0% during the fourth quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after acquiring an additional 96 shares during the period. Innealta Capital LLC bought a new position in Neurocrine Biosciences in the second quarter valued at about $30,000. Finally, EdgeRock Capital LLC acquired a new stake in Neurocrine Biosciences in the fourth quarter worth about $31,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 2.8 %

NBIX stock opened at $141.18 on Wednesday. The firm has a market cap of $14.21 billion, a PE ratio of 38.89 and a beta of 0.37. Neurocrine Biosciences has a 1 year low of $99.98 and a 1 year high of $150.39. The company has a fifty day simple moving average of $139.25 and a 200 day simple moving average of $138.13.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.62). The company had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. As a group, analysts forecast that Neurocrine Biosciences will post 4.22 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.